Skip to content
DataLookout
Menu

ECLIPSENCT06354868

A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Sep 30, 2027 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Start date changed from estimate of Sep 2024 to Mar 24, 2025
    • Eligibility criteria expanded, about 79 words
    • Enrollment increased: 158 → 198 participants
    • Trial sites expanded: 0 → 9 locations
    • Secondary endpoint revised
    • Study description revised
  2. Notable Start date: Jun 2024 to Sep 2024v3
  3. Notable Primary endpoint revised
    • Secondary endpoint revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The association between BioEP and self-reported seizure control
Timeframe: 6 months

Secondary (1)

Association between the 6-month change from baseline in BioEP result and the patients reported global impression of change

Sites

9 sites in 1 country